🔥 CAPR DD: The Little Biotech That Could (Or Could Not) – A Degenerate’s Guide to a $14 Lottery Ticket 🎢
**Ticker**: CAPR (Capricor Therapeutics)
**Current Price (Mar 2025):** \~$14
**Market Cap:** \~$580M
**My Position:** 835 Sept $15 Calls @ $5.50 (**Yes, I YOLO’d \~$459K**)
**Sector:** Biotech / Rare Disease
**Catalyst:** FDA **Priority Review** for first-in-class **DMD therapy** – **PDUFA date Aug 31, 2025**
**TL;DR:** 🚀 **FDA decision coming in August for a rare disease therapy** with **no direct competition.** Company **fully funded till 2027** (so **no rug-pull dilution** incoming), has a **big pharma partner handling commercialization,** and analysts are **way more bullish than the market.** Meanwhile, **shorts are betting against it despite FDA giving it the fast lane.** If this goes through, 💰💰. If it fails, 💀.
This is **a classic biotech play**: **under-the-radar, asymmetric risk/reward, and trading like it’s already dead when it’s not.** So, why hasn’t this thing **mooned** yet?
**🎯 The Big Catalyst – FDA’s Priority Review**
**WTF Happened?**
On **March 4, 2025**, Capricor ($CAPR) announced that the **FDA accepted its BLA** (Biologics License Application) for **Deramiocel** (CAP-1002), an investigational **cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy.**
💡 **Key FDA facts:**
✅ **Priority Review** – This means **FDA cut the review time from 10 months to 6.** VIP fast lane. 🏎️
✅ **PDUFA date set for Aug 31, 2025** – The final decision deadline. 🗓️
✅ **No review issues flagged yet.** No AdCom (yet). If **no AdCom by summer,** that’s bullish. 🚀
✅ **If approved, it would be the first therapy specifically for DMD heart disease.**
**Why It Matters**
👶 **DMD is a brutal genetic disorder that leads to early death (heart failure in teens/20s).**
💊 **There are NO approved drugs for the heart problems in DMD.** Deramiocel could **extend lives.**
📈 **FDA already fast-tracked this under multiple designations** (RMAT, Orphan, Rare Pediatric).
💡 The FDA doesn’t hand out **Priority Review & Rare Disease incentives** unless they think the drug **has a real shot.**
**The Stock’s Reaction? Total Apathetic Shrug. 🤨**
When **FDA acceptance was announced**, CAPR **barely moved (+3% close).** This was after a **pre-market +14% spike.** Instead of 🚀, we got… meh.
**WTF?**
**🤔 Why Is This Still Trading Like a Penny Stock?**
1️⃣ **BLA Acceptance Was “Priced In”** – CAPR ran from **\~$4 to the mid-teens** in late 2024 as traders **anticipated** the FDA submission. So **no new buying frenzy.**
2️⃣ **Shorts Are Doubting FDA Approval** – There’s a **high short interest (\~20% of the float)**, likely betting **FDA will demand more data.**
3️⃣ **Biotech Market Sentiment is Trash Right Now** – The sector is struggling. Risk-off mode.
4️⃣ **Earnings Are Coming – Guidance Will Matter** – Market might be waiting to hear about cash burn & commercialization plans.
💡 **Why is the borrow rate climbing?** That means **hedgies are paying more to bet against this.**
**💰 The Financials – No Dilution Incoming (Unlike Most Biotech Wrecks)**
Most **small-cap biotechs bleed out before FDA decisions** because they need **cash injections (= stock offerings = price nukes).** But CAPR **doesn’t need money until at least 2027.**
💰 **Cash:** \~$175M (after big 2024 raise)
🔥 **Runway:** 2027 (even at high burn)
📉 **No Debt / No ATM Financing** – No surprise 5pm “surprise dilution” announcements.
💸 **Partner Funding:** Nippon Shinyaku (Japanese pharma) has **already invested $15M in equity** at a 20% premium & will handle global commercialization.
🚀 **If Deramiocel gets FDA approval, CAPR gets:**
✅ **$100M+ just from selling the Priority Review Voucher** (PRV)
✅ **Milestone payments from Nippon Shinyaku ($705M total potential)**
✅ **Royalties on sales** (double-digit %)
**🔥 The Big Question: What’s the Market Missing?**
🔍 **Current Market Cap:** \~$580M
📊 **Analysts’ Price Targets:** **$34-$77**
👀 **Short Interest:** \~8.16M shares (20.4% of float)
📈 **Stock Should Be Priced Higher If Approval Odds Are Good**
**📜 Biotech Playbook: Past FDA Approval Trades**
✔️ **Sarepta (SRPT) 2016 – 131% gain in one month** when their DMD drug got approved despite a shaky FDA panel.
✔️ **Spark (ONCE) 2017 – FDA approval → Acquired by Roche for $4.3B.**
✔️ **Krystal Biotech (KRYS) 2023 – Ran from \~$70 to $130 pre-FDA approval.**
🚀 **CAPR is following a similar setup.**
**🎲 The Play – How Degenerates Could Trade This**
1️⃣ **Run-Up Trade:** Buy shares/calls leading into August & sell before FDA decision.
2️⃣ **Binary Bet:** Hold through the PDUFA for **moonshot approval or fiery death.**
3️⃣ **Straddle/Strangle:** If you expect a **massive move** but not sure which way.
4️⃣ **Wheel It:** Sell cash-secured puts to collect premium from high IV.
**If approved,** this could be a **multi-bagger stock overnight.** If rejected, 💀.
**🚨 Final Ape Thoughts**
🔥 **FDA Priority Review isn’t given out lightly.**
🔥 **No competing therapies exist.**
🔥 **CAPR is fully funded into 2027, so dilution isn’t a near-term risk.**
🔥 **Stock is undervalued compared to potential payout.**
🚀 **The trade? If the market realizes this is actually a solid biotech setup, it could run. If not, the PDUFA itself will be the make-or-break moment.**
🦍 **Who else is loading up? Let’s discuss.**
**📌 TL;DR**
• **FDA Priority Review → Decision due Aug 31, 2025.**
• **If approved, first-in-class drug with no competition.**
• **Company has cash till 2027. No dilution threat pre-PDUFA.**
• **Market is skeptical despite FDA green light & strong partnerships.**
• **Short interest is high, but could be wrong (like SRPT, ONCE, KRYS).**
• **Massive upside if approved, nuclear downside if rejected.**
Disclosure: I hold 835 September $15 calls. I’m just a crayon-eating degenerate, not a financial advisor. **This is biotech gambling.** Do your own DD. 🦍🚀
**💬 Drop Your Thoughts – Is This a $30 Stock in the Making or a Future Biotech Bag?**
https://preview.redd.it/ghdyp4312xme1.png?width=1290&format=png&auto=webp&s=0e7e6e36d6b8d53d3b4d346131e3ca94105e5b2c